Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cephalon
Patients randomly assigned to chemotherapy alone received the second course of induction chemotherapy as soon as clinically indicated; patients randomly assigned to receive chemotherapy plus sequential lestaurtinib had lestaurtinib withheld for 3 days (72 hours) before the start of the second 5-day course of chemotherapy and resumed lestaurtinib treatment 2 days (48 hours) after the final administration of the second course of chemotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
cytological confirmation of AML;
relapsed disease following first CR of 1 month(30days)to 24 months(730days). The time from first relapse to study entry (start of first course of induction chemotherapy) must be no longer than 30days;
confirmation of FLT-3 activating mutation positive status after point of initial relapse;
aged 18 years or older;
written informed consent;
ability to understand and comply with study restrictions;
no comorbid conditions that would limit life expectancy to less than 3 months;
ECOG Performance Score of 0, 1,or 2;
women must be neither pregnant nor lactating, and either of non-childbearing potential or using adequate contraception with a negative pregnancy test at study entry
You may not be if
bilirubin \> 2x ULN;
ALT/AST \> 3x ULN;
serum creatinine \> 1.5 mg/dL;
resting ejection fraction of left ventricle l \< 45%(applies only to patients scheduled to receive mitoxantrone, etoposide, and cytarabine \[MEC\];
untreated or progressive infection;
any physical or psychiatric cdtn that may compromise participation in the study;
known CNS involvement with AML;
any previous treatment with a FLT-3 inhibitor;
requires current treatment for HIV with protease inhibitors;
active GI ulceration or bleeding;
use of an investigational drug that is not expected to be cleared by the start of CEP-701 treatment
Clareo Health | Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
